Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 10/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362760 | 1.00 | HTR2A (0.34) | HTR2AHTR2CHTR2BESR1ESR2 | |
| SCHEMBL10098029 | 1.00 | HTR2A (0.34) | HTR2AHTR2CHTR2BESR1ESR2 | |
| SCHEMBL15953600 | 1.00 | HTR2A (0.34) | HTR2AHTR2CHTR2BESR1ESR2 | |
| SCHEMBL15312086 | 0.91 | ESR1 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| SCHEMBL2713088 | 0.91 | ESR1 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| SCHEMBL10074001 | 0.91 | ESR1 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| SCHEMBL30362814 | 0.91 | ESR1 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| SCHEMBL24053246 | 0.90 | PTPN1 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| Me-344 SCHEMBL29370582 | 0.87 | ESR2 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 | |
| Me-344 SCHEMBL30276333 | 0.87 | ESR2 (0.36) | ESR1ESR2PTPN1CYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | Aardvark Therapeutic, Inc. (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| WO-2016126618-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2635121-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Marshall Edwards, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | HTR2A 4286/4885HTR2C 4255/4885HTR2B 4406/4885 |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | CYP19A1, HSD17B11, BRCA1 | HTR2A 2413/4885HTR2C 2543/4885HTR2B 2121/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | HTR2A 3770/4885HTR2C 4024/4885HTR2B 3566/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | HTR2A 3771/4885HTR2C 3254/4885HTR2B 3773/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | HTR2A 3771/4885HTR2C 3254/4885HTR2B 3773/4885 |
| US-12329739-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | HTR2A 3771/4885HTR2C 3254/4885HTR2B 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.